Exact Sciences Analysts Slash Their Forecasts After Q2 Results
Exact Sciences Analysts Slash Their Forecasts After Q2 Results
"Our second quarter results show the dedication of Exact Sciences' world-class team and the power of our unique platform," said Kevin Conroy, chairman and CEO. "We delivered answers to more patients and healthcare professionals than ever before, achieved record revenue and profitability, and advanced each of our key pipeline programs. Momentum continues to build, fueling our purpose to help eradicate cancer."Exact Sciences Corporation (NASDAQ:EXAS) reported better-than-expected second-quarter financial results on Wednesday.
精密科学公司（NASDAQ:EXAS）周三发布了超出预期的第二季度财务业绩报告。
Exact Sciences reported quarterly losses of 9 cents per share, which beat the analyst consensus estimate of losses of 32 cents by 71.88%.The company reported quarterly sales of $699.264 million which beat the analyst consensus estimate of $690.003 million. Screening revenue was $532 million, a 15% increase, and Precision Oncology revenue was $168 million, an increase of 6%.
Exact Sciences 每股亏损9美分，比分析师预期的每股亏损32美分高出71.88%。公司本季度销售额为69926.4万美元，超过分析师预估的69000.3万美元。筛查收入为53200万美元，增长15%，精密肿瘤学收入为16800万美元，增长6%。
Also, the company announced an exclusive license agreement with TwinStrand Biosciences.
此外，公司宣布与TwinStrand Biosciences签订了独家许可协议。
"Our second quarter results show the dedication of Exact Sciences' world-class team and the power of our unique platform," said Kevin Conroy, chairman and CEO. "We delivered answers to more patients and healthcare professionals than ever before, achieved record revenue and profitability, and advanced each of our key pipeline programs. Momentum continues to build, fueling our purpose to help eradicate cancer."
“我们第二季度的业绩展示了 Exact Sciences 世界一流团队的专注以及我们独特平台的强大，”首席执行官Kevin Conroy表示。“我们为更多患者和医疗保健专业人员提供了答案，创造了记录的收入和盈利，并推进了我们的关键管道项目。势头持续增强，推动我们的目标消除癌症。”
Exact Sciences shares gained 23.2% to trade at $56.27 on Thursday.
Exact Sciences 股价在周四上涨23.2%，至56.27美元。
These analysts made changes to their price targets on Exact Sciences following earnings announcement.
这些分析师在发布财报后调整了对Exact Sciences的目标股价。
- Stifel analyst Daniel Arias maintained Exact Sciences with a Buy rating, while cutting the price target from $100 to $82.
- Benchmark analyst Bruce Jackson maintained Exact Sciences with a Buy rating and lowered the price target from $91 to $67.
- Stifel分析师Daniel Arias保持买入评级，将目标股价从100美元下调至82美元。
- Benchmark分析师Bruce Jackson保持买入评级，将目标股价从91美元下调至67美元。
Read More:
阅读更多：
- Top 3 Health Care Stocks That Are Set To Fly This Quarter
- 前三家医疗保健股票在本季度有望上涨
